TY  - CHAP
AU  - Venice Wing Tung Ho
AU  - Hor Yue Tan
AU  - Ning Wang
AU  - Yibin Feng
ED  - Huan Ren
Y1  - 2019-01-21
PY  - 2019
T1  - Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies
N2  - Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment.
BT  - Tyrosine Kinases as Druggable Targets in Cancer
SP  - Ch. 5
UR  - https://doi.org/10.5772/intechopen.82513
DO  - 10.5772/intechopen.82513
SN  - 978-1-78984-809-0
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-05-10
ER  -